<DOC>
	<DOCNO>NCT00735943</DOCNO>
	<brief_summary>The objective observational study evaluate effectiveness safety Macugen treatment wet age-related macular degeneration ( AMD ) Indian patients.Prospective , Observational , Non-interventional Study . The period observation study 1 year</brief_summary>
	<brief_title>Macugen Observational Study</brief_title>
	<detailed_description>To eligible enrollment study , patient must receive first injection Macugen intravitreal least one eye treatment wet age-related macular degeneration ( AMD ) . The decision prescribe Macugen necessarily precede independent decision enroll patient study . If eyes patient receive injection Macugen , one eye include study . If eye receive first injection Macugen initiation study , first treat eye include analysis . If one eye already receive Macugen study start second eye receive injection study initiation , second eye include analysis . The study prematurely discontinue due delay meet pre-defined protocol recruitment milestone August 30 , 2010 . There safety concern regard study decision terminate trial .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>To eligible enrollment study , patient must receive first injection Macugen intravitreal least one eye treatment wet agerelated macular degeneration ( AMD ) . Active suspect ocular periocular infection . Known hypersensitivity pegaptanib sodium excipient product .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Pegaptanib</keyword>
	<keyword>macular degeneration</keyword>
	<keyword>vascular endothelial growth factor</keyword>
</DOC>